TF is already a clinically well-validated target in a broad range of solid tumors, including ovarian and cervical cancers, NSCLC, colorectal cancer, pancreatic cancer, and prostate carcinomas, where its prevalent expression has been associated with poor prognosis [219,220,221]. Here, TF is linked to cervical carcinoma.